Research

Cure SMA Convenes Working Group to Discuss Biomarkers for SMA

July 1, 2021
Posted in ,

The advent of three approved SMN-upregulating therapeutics for spinal muscular atrophy has dramatically changed the natural history of the disease. There are, however, many uncertainties […]

Read More ›

Novartis Data Demonstrate Age-Appropriate Development When Zolgensma Is Used Presymptomatically and Rapid, Clinically Meaningful Efficacy in Symptomatic Children

June 21, 2021
Posted in , , ,

Novartis recently announced data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA). […]

Read More ›

Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 SMA

June 11, 2021
Posted in , , ,

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an oral […]

Read More ›

New Genentech Data for Evrysdi Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with SMA

June 11, 2021
Posted in , , ,

Genentech, a member of the Roche Group, today announced new interim data from two studies of Evrysdi® (risdiplam)—JEWELFISH and RAINBOWFISH. Genentech leads the clinical development of […]

Read More ›

Biogen Presents New Spinraza Data at the 2021 Virtual SMA Conference

June 10, 2021
Posted in , ,

Biogen Inc., today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing the strength of […]

Read More ›

Cure SMA Publishes Manuscript on SMA Awareness, Screening, and Referral Patterns Amongst Pediatricians

May 28, 2021
Posted in , ,

In a May 2021 issue of BMC Pediatrics, Cure SMA published a manuscript, titled “Awareness screening and referral patterns among pediatricians in the United States […]

Read More ›

Cure SMA-Funded Researchers at Ohio State University Publish Paper on Effect of Nusinersen in Adults with SMA

May 10, 2021
Posted in ,

Dr. Bakri Elsheikh and colleagues at The Ohio State University have published a paper in the Journal, Frontiers in Neurology, titled “Safety, Tolerability, and Effect of Nusinersen […]

Read More ›

Cure SMA-Funded Researchers at Columbia University Publish Paper on Fatigue in SMA

April 26, 2021
Posted in ,

Dr. Jacqueline Montes and colleagues at Columbia University—part of the Pediatric Neuromuscular Clinical Research Network (PNCRN) funded by Cure SMA—have published a paper in the […]

Read More ›

Cure SMA Attends Spring 2021 Professional Organization Conferences to Promote Findings from Industry Collaboration Initiatives

April 22, 2021
Posted in ,

Cure SMA is pleased to announce its participation in the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference (March 15-18, 2021) and the […]

Read More ›

Genentech Shares New Evrysdi Data on Improved Motor Function and Survival in Babies with SMA Type 1

April 21, 2021
Posted in , , ,

Genentech, a member of the Roche Group, has shared new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) […]

Read More ›
Scroll to Top